ENLV
Enlivex Therapeutics Ltd. [ENLV] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ENLV Stock Summary
Top 10 Correlated Stocks
ENLV
In the News
ENLV Financial details
Company Rating
-
Market Cap
29.37M
Income
-29.5M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
71
Optionable
No
Shortable
Yes
Earnings
24 Jun 2024
P/E
-2.26
Forward P/E
-
PEG
0.73
P/S
-
P/B
1.57
P/C
-
P/FCF
-2.35
Quick Ratio
7.34
Current Ratio
7.34
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.59
EPS next Y
-
EPS next Q
-
EPS this Y
-32.47%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
53.13%
-
-
-
-
SMA20
-9.89%
SMA50
-25.45%
SMA100
-20.39%
Inst Own
-
Inst Trans
-
ROA
-57%
ROE
-57%
ROC
-0.63%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.2-4.59
52W High
-80.75%
52W Low
-23%
RSI
36.83
Rel Volume
2.42
Avg Volume
132.06K
Volume
319.43K
Perf Week
-3.93%
Perf Month
-29.36%
Perf Quarter
-22.23%
Perf Half Y
-22.99%
-
-
-
-
Beta
1.055
-
-
Volatility
0.02%, 0.06%
Prev Close
-4.12%
Price
0.77
Change
-7.57%
Company Profile
- Volume Average 132.06K
- Market Capitalization 29.37M
- Employee 71
- CEO Dr. Oren Hershkovitz Ph.D.
- Headquarters Ness Ziona,IL
- IPO Date 2014-07-31
-
Website
https://www.enlivex.com 
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
